Ruiz-Domínguez R, Oropeza-Borges M, Blanco-Villarte R

Language: Spanish
References: 16
Page: 139-142
PDF size: 444.87 Kb.

ABSTRACT

Many diseases can cause disseminated intravascular coagulation (DIC). Sepsis is the most common and most studied. DIC is associated with multiple types of solid tumors, like prostatic adenocarcinoma. Association of prostate cancer with DIC results in a poor prognosis. An ideal or specific treatment has not been found yet. Current treatment focuses on symptomatic management of DIC and a combination of LHRH agonists and anti-androgenic drugs. Two cases of prostatic adenocarcinoma associated with chronic DIC, successfully treated with heparin and transfusion of packed red blood cells, platelets, cryoprecipitate and fresh frozen plasma are reported.

REFERENCES

1. Kusuma B ad Schulz TK. Acute Disseminated Intravascular Coagulation. Hospital Physician 2009:35-40.

2. García FJ, López BF y Ais C. Tratamiento a largo plazo de coagulación intravascular diseminada crónica con heparina de bajo peso molecular. An Med Interna 2003;20(4):191-194.

3. Levi M, De Jonge E and Meijers J. The diagnosis of disseminated intravascular coagulation. Blood Reviews 2002;16(4):217-223.

4. Levi M and Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999;341(8):586-592.

5. Levi M. Disseminated intravascular coagulation. Crit Care Med 2007;35:2191-2195.

6. Cornet AD, Smit EG, Beishuizen A and Groeneveld AB. The role of heparin and allied compounds in the treatment of sepsis. Thromb Haemost 2007;98:579-586.

7. Franchini M, Lippi G and Manzato F. Recent acquisitions in the pathophysiology, diagnosis and treatment of disseminated intravascular coagulation. Thromb J 2006;4:4.

8. Gómez TR, Claros GI, Echevarria FI, Zanabili Y, Alvarez Ch M, et al. Coagulación intravascular diseminada como forma de presentación de adenocarcinoma prostático. An Med Interna 2002;19(1):66-68.

9. Adamson AS, Witherom RO, Francis JL and Snell ME. Coagulopathy in the prostate cancer patient: prevalence and clinical relevance. Ann R Coll Surg Engl 1993;75(2):100-104.

10. Cooper DL, Sandler AB, Wilson LD and Duffy TP. Disseminated intravascular coagulation and excessive fibrinolysis in patients with metastatic prostate cancer. Response to epsilon aminocaproic acid. Cancer 1992;70(3):656-658.

11. Cabane J, Etariah C, Louvet C, Robert A, Blum L, et al. Coagulation intravasculaire disséminée associée au cancer de la prostate. La Revee de Medecine Interne 1995;16(3):219-224.

12. Chargari C, Vedrine L, Bauduceau O, Le Moulec S, Fasyolle M, et al. Cancer de prostate et coagulation intravasculaire disséminée: une reuve de la littérature. Progrés en Urologie 2008;18(1):9-13.

13. Pinto F, Brescia A, Sacco E, Volpe A, Gardi M, et al. Disseminated intravascular coagulation secondary to metastatic prostate cancer: case report and review of the literature. Arch Ital Urol Androl 2009;8(4):212-214.

14. Valencia E, Levi M. Disfunciones hematológicas en pacientes con patologías oncológicas y Actualización en CID en el paciente críticamente enfermo. Disfunción hematológica del paciente críticamente enfermo. Editorial Distribuna, Bogotá-Colombia 2012:57-66,203-205.

15. Dame D, Ragan M, Kalmár K, Kovács L, Varga E, et al. Metastatic prostate cancer complicated with chronic disseminated intravascular coagulopathy causing acute renal failure, mimicking thrombotic thrombocytopenic purpura and hemolytic uremic syndrome: pathomechanism, differential diagnosis and therapy related to a case. Magy Onkol 2010;54(4):351-357.

16. Becopoulos T, Kranides A, Mandalaki-Yianitsiotis T, Louizou K, Panagiotopoulou E and Dimopoulos C. Syndrome de coagulation intra-vasculaire disséminée (CID) et cancer de la prostate. J D Urologie 1980;86:467-470.